The BioLegend Campus Extension started in 2015 with a four-year master plan to privatize a public street and convert the existing 7.5-acre, four-parcel plot into an eight-acre biotechnology campus.

San Diego-based BioLegend Inc., a biotech firm that develops antibodies and reagents used in biomedical research, has broken ground on the second phase of its Sorrento Mesa campus. Scheduled for ...

SAN DIEGO, CA--(Marketwire - Mar 7, 2013) - BioLegend in San Diego, CA, a leading provider of antibodies and reagents for biomedical research, has been granted ISO 9001:2008 certification for ...

BioLegend can breathe a bit easier. The San Diego biological research products supplier, which had been cramped for space, opened a new and larger headquarters this week. BioLegend has more than 500 ...

New Jersey-based drug development services company Covance Inc. (CVD) recently divested its antibody services unit to antibodies and reagents developer and manufacturer BioLegend, Inc. However, ...

SAN DIEGO--(BUSINESS WIRE)--BioLegend, leading provider of world-class biological reagents and tools that enable life science discovery from research to cure, today announced the opening of its new ...

PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...

PerkinElmer Inc. said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. PerkinElmer said Monday the transaction is ...

Massachusetts life science firm PerkinElmer plans to acquire San Diego antibody company BioLegend for $5.25 billion, according to an announcement from the company on Monday. About $2.2 billion of the ...

(Reuters) - Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash ...

SAN DIEGO--(BUSINESS WIRE)-- BioLegend, Inc., a provider of antibodies and reagents for biomedical research, announced today the release of over fifty Brilliant Violet 421™ antibody conjugates for use ...

Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash-and-stock ...